Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.69, No.2, p.430–442, 2022 |
||
| Title: Prognostic potential of circulating miR-93-5p in patients with colorectal cancer liver metastases | ||
| Author: Jovana Despotović, Aleksandar Bogdanović, Sandra Dragičević, Danijel Galun, Zoran Krivokapić, Aleksandra Nikolić | ||
| Abstract: This study aimed to examine the expression pattern of tumoral and circulating miR-93-5p in patients with colorectal cancer (CRC) liver metastasis (CRLM) and to explore its predictive and prognostic potential. CRLM tissue, surrounding non-tumor liver tissue, and serum were obtained from 35 patients with CRLM. The expression pattern of tissue and circulating miR-93-5p in patients with CRLM was determined using quantitative polymerase chain reaction, using miR-16-5p for normalization. Sample-based cut-off values for CRLM and serum miR-93-5p expression were calculated using Receiver Operating Characteristic curve analysis to stratify the patients into high and low miR-93-5p expression groups which were that compared with patients’ clinicopathological data, therapy response, one-year disease-free survival, and disease recurrence. Relative miR-93-5p expression was higher in CRLM in comparison to the non-metastatic liver tissue (p < 0.001). CRLM miR-93-5p expression showed moderate negative correlation with carcinoembryonic antigen levels (r = -0.406; p = 0.016). There were no differences in high-/low-miR-93-5p expression and therapy responders vs. non-responders, which was confirmed in vitro using metastatic and normal colonic cells SW620 and HCEC-1CT, respectively. No difference was observed in one-year recurrence-free survival in patients with high vs. low miR-93-5p expression in CRLM or serum. However, high miR-93-5p serum levels were significantly associated with early disease recurrence (p = 0.035). In conclusion, miR-93-5p serum levels could be potentially used as a prognostic factor for early disease recurrence in CRLM patients. |
||
| Keywords: metastatic colorectal cancer; colorectal cancer liver metastasis; microRNA; miR-93-5p; prognostic biomarker | ||
| Published online: 17-Jan-2022 | ||
| Year: 2022, Volume: 69, Issue: 2 | Page From: 430, Page To: 442 | |
| doi:10.4149/neo_2021_210603N749 |
||
|
|
 download file |
|